Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Jun 2, 2014	Biocept Expands Breast Cancer Offering Blood-based OncoCEE-BR™ Platform now Includes Estrogen Receptor Testing SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today	View HTML Biocept Expands Breast Cancer Offering 13.2 KB
Toggle Summary Aug 6, 2014	Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy Quest Diagnostics and GE Healthcare Veteran Amy McNeal Brings Experience to Biocept Team	View HTML Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy 16.1 KB
Toggle Summary Aug 14, 2014	Biocept Provides Second Quarter Operational Update SAN DIEGO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities	View HTML Biocept Provides Second Quarter Operational Update 15.5 KB
Toggle Summary Sep 3, 2014	Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe Key Microfluidic Channel Patent Granted to Biocept in Europe	View HTML Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe 13 KB
Toggle Summary Sep 4, 2014	Biocept to Present at Upcoming Investor Conferences SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a	View HTML Biocept to Present at Upcoming Investor Conferences 10 KB
Toggle Summary Sep 18, 2014	Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells Patent Approval Further Strengthens Biocept's IP Position in Personalized Cancer Treatment in East-Asia	View HTML Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells 14 KB
Toggle Summary Sep 30, 2014	Biocept to Present at the 13th Annual BIO Investor Forum SAN DIEGO , Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall , Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 13th Annual BIO Investor Forum 10 KB
Toggle Summary Oct 7, 2014	Biocept Expands Collaboration With MD Anderson Cancer Center Biocept's OncoCEE(TM) Platform Enhances Ovarian Cancer Research	View HTML Biocept Expands Collaboration With MD Anderson Cancer Center 13.3 KB
Toggle Summary Oct 13, 2014	Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel , Oct. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd.	View HTML Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells 18.5 KB
Toggle Summary Nov 6, 2014	Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for	View HTML Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results 12.5 KB

Investor Relations

Press Releases

Contact Biocept, Inc.